In a nationwide cohort study in the USA involving 2593 NSCLC patients, it was found that the KRAS/KEAP1 co-mutation was also associated with low expression of PD-L1 and poor prognosis after ICIs treatment, and triple mutation of KRAS/KEAP1/LKB1 exhibited the poorest outcome [299]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.